Abvc Biopharma (ABVC) Retained Earnings (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Retained Earnings came in at $499650.0 in Q1 2026, up 12.49% YoY from $444172.0 in Q1 2025, and up 100.65% on a QoQ basis from -$76.9 million in Q4 2025.
Abvc Biopharma (ABVC) Retained Earnings (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Retained Earnings data on file, last reported at $499650.0 in Q1 2026.
- Quarterly Retained Earnings rose 12.49% year-over-year to $499650.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $499650.0 (up 12.49% YoY) and the FY2025 annual result came in at -$76.9 million, down 11.47% from the prior year.
- Retained Earnings advanced to $499650.0 in Q1 2026, from -$76.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $93.9 million in Q3 2025 to a low of -$76.9 million in Q4 2025.
- A 5-year average of $1.1 million and a median of $444172.0 in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 261.19% — and 2024, when it slumped 13452.35%.
- Tracing ABVC's Retained Earnings over 5 years: stood at -$54.9 million in 2022, then soared by 100.94% to $516387.0 in 2023, then tumbled by 13452.35% to -$68.9 million in 2024, then declined by 11.47% to -$76.9 million in 2025, then soared by 100.65% to $499650.0 in 2026.
- The last three Retained Earnings figures came in at $499650.0 (Q1 2026), -$76.9 million (Q4 2025), and $93.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 4.38 Bn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 97.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.72 Mn |
| Mar 31, 2026 | 499,650.00 |
| Dec 31, 2025 | -76.86 Mn |
| Sep 30, 2025 | 93.91 Mn |
| Jun 30, 2025 | -72.05 Mn |
| Mar 31, 2025 | 444,172.00 |
| Dec 31, 2024 | -68.95 Mn |
| Sep 30, 2024 | 78.25 Mn |
| Jun 30, 2024 | -70.37 Mn |
| Mar 31, 2024 | 233,323.00 |
| Dec 31, 2023 | 516,387.00 |
| Sep 30, 2023 | 80.66 Mn |
| Jun 30, 2023 | 68.08 Mn |
| Mar 31, 2023 | 68.05 Mn |
| Dec 31, 2022 | -54.90 Mn |
| Sep 30, 2022 | -50.04 Mn |
| Jun 30, 2022 | 66.24 Mn |
| Mar 31, 2022 | -44.48 Mn |
| Dec 31, 2021 | -38.48 Mn |
| Sep 30, 2021 | 981,718.00 |